Risks, Costs, and Alternatives to Platelet Transfusions

References

• Pisciotto P T, Benson K, Hume H, Glassman A B, Oberman H, Popovsky M, Hines D, Anderson K. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995; 35: 498–502
   PubMed Web of Science ®Google Scholar
• Webb I J, Anderson K C. Transfusion support in acute leukemias. Semin Oncol 1997; 24: 141–146
   PubMed Web of Science ®Google Scholar
• Wallace E L, Surgenor D M, Hao H S, An J, Chapman R H, Churchill W H. Collection and transfusion of blood and blood components in the United States, 1989. Transfusion 1993; 33: 139–144
   PubMed Web of Science ®Google Scholar
• Wallace E L, Churchill W H, Surgenor D M, An J, Cho G, McGurk S, Murphy L. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35: 802–812
   PubMed Web of Science ®Google Scholar
• Baer M R, Bloomfield C D. Controversies in transfusion medicine. Prophylactic platelet transfusion: pro. Transfusion 1992; 32: 377–380
   PubMed Web of Science ®Google Scholar
• Gordon M S, Hoffman R. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 1992; 80: 302–307
   PubMed Web of Science ®Google Scholar
• Kuter D J. Hemorrhagic disorders II. Platelets. Hematology, WS Beck. MIT Press, Cambridge, MA 1991; 543–576
   Google Scholar
• Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870–1875
   PubMed Web of Science ®Google Scholar
• Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion therapy for patients with acute leukemia. Lancet 1991; 338: 1223–1226
   PubMed Web of Science ®Google Scholar
• Wandt H, Frank M, Ehninger G, Schneider Brack C. N., Daoud A, Fackler-Schwalbe I, Fischer J, Gackle R, Geer T, Harms P, Loftier B, Ohl S, Otremba B, Raab M, Schonrock-Nabulsi P, Strobel G, Winter R, Link H. Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91: 3601–3606
   PubMed Web of Science ®Google Scholar
• Bordin J O, Heddle N M, Blajchman M A. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84: 1703–1721
   PubMed Web of Science ®Google Scholar
• Brubaker D B. Clinical significance of white cell antibodies in febrile nonhemolytic transfusion reactions. Transfusion 1990; 30: 733–737
   PubMed Web of Science ®Google Scholar
• Dzieczkowski J S, Barrett B B, Nester D, Campbell M, Cook J, Sugrue M, Andersen J W, Anderson K C. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995; 35: 20–25
   PubMed Web of Science ®Google Scholar
• Mangano M M, Chambers L A, Kruskall M S. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol 1991; 95: 733–738
   PubMed Web of Science ®Google Scholar
• Stack G, Snyder E L. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34: 20–25
   PubMed Web of Science ®Google Scholar
• Muylle L, Joos M, Wouters E, De Bock R, Peetermans M E. Increased tumor necrosis factor α (TNFα), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNFα and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195–199
   PubMed Web of Science ®Google Scholar
• Heddle N M, Klama L, Singer J, Richards C, Fedak P, Walker I, Kelton J G. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331: 625–628
   PubMed Web of Science ®Google Scholar
• Muylle L, Peetermans M E. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66: 14–17
   PubMed Web of Science ®Google Scholar
• Friedberg R C, Donnelly S F, Boyd J C, Gray L S, Mintz P D. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993; 81: 3428–3434
   PubMed Web of Science ®Google Scholar
• Bishop J F, McGrath K, Wolf M M, Matthews J P, De Luise T, Holdsworth R, Yuen K, Veale M, Whiteside M G, Cooper I A, Szer J. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71: 383–387
   PubMed Web of Science ®Google Scholar
• Yankee R A, Graff K S, Dowling R, Henderson E S. Selection of unrelated compatible platelet donors by lymphocyte HLA matching. N Engl J Med 1973; 288: 760–764
   PubMed Web of Science ®Google Scholar
• Sintnicolaas K, Vriesendorp H M, Sizoo W, Stenfert Kroese W F, Haije W G, Hop W CJ, Abels J, Lowenberg B. Delayed alloimmunization by random single donor platelet transfusions: a randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia. Lancet 1981; 1: 750–754
   PubMed Web of Science ®Google Scholar
• Van Marwijk Kooy M, Van Prooijen H C, Moes M, Bosma-Stants I, Akkerman J W. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991; 77: 201–205
   PubMed Web of Science ®Google Scholar
• Moroff G, Garratty G, Heal J M, MacPherson B R, Stroncek D, Huang S T, Ho W, Petz L D, Leach M F, Lennon S S, Rowe J M, Saleh M N, Arndt P, Foley K, Masel D, Postoway N. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992; 32: 633–640
   PubMed Web of Science ®Google Scholar
• Grijzenhout M A, Aarts-Riemens M I, De Grujil F R, Van Weelden H, Van Proojien H C. UVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients. Blood 1994; 84: 3524–3531
   PubMed Web of Science ®Google Scholar
• TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861–1869
   PubMed Web of Science ®Google Scholar
• Blajchman M A, Bardossy L, Carmen R A, Goldman M, Heddle N M, Singal D P. An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. Blood 1992; 79: 1371–1375
   PubMed Web of Science ®Google Scholar
• Kickler T, Braine H G, Piantadosi S, Ness P M, Herman J H, Rothko K. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990; 75: 313–316
   PubMed Web of Science ®Google Scholar
• Webb I J, Anderson K C. Transfusion-associated graft-versus-host disease. Transfusion Reactions, MA Popovsky. American Association of Blood Banks Press, Bethesda, MD 1996; 185–204
   Google Scholar
• Shivdasani R A, Haluska F G, Dock N L, Dover J S, Kineke E J, Anderson K C. Graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993; 328: 766–770
   PubMed Web of Science ®Google Scholar
• Anderson K C, Weinstein H J. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315–321
   PubMed Web of Science ®Google Scholar
• FDA. Memorandum to registered blood establishments: recommendations regarding license amendments and procedures for irradiating blood products. 1993
   Google Scholar
• Anderson K C, Goodnough L T, Sayers M, Pisciotto P T, Kurtz S R, Lane T A, Anderson C S, Silberstein L E. Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease. Blood 1991; 77: 2096–2102
   PubMed Web of Science ®Google Scholar
• Akahoshi M, Takanashi M, Masuda M, Yamashita H, Hidano A, Hasegawa K, Kasajima T, Shimizu M, Motoji T, Oshimi K, Mizoguchi H. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992; 32: 169–172
   PubMed Web of Science ®Google Scholar
• Blajchman M A, Bardossy L, Carmen R, Sastry A, Singal D P. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993; 81: 1880–1882
   PubMed Web of Science ®Google Scholar
• Vamvakas E, Moore S B. Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta-analysis. Transfusion 1993; 33: 754–765
   PubMed Web of Science ®Google Scholar
• Vamvakas E C, Moore S B. Blood transfusion and postoperative septic complications. Transfusion 1994; 34: 714–727
   PubMed Web of Science ®Google Scholar
• Vignali A, Braga M, Gianotti L, Radaelli G, Gentilini O, Russo A, Di Carlo V. A single unit of transfused allogenic blood increases postoperative infections. Vox Sang 1996; 71: 170–175
   PubMed Web of Science ®Google Scholar
• Bordin J O, Bardossy L, Blajchman M A. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood 1994; 84: 344–348
   PubMed Web of Science ®Google Scholar
• Jensen L S, Andersen A J, Christiansen P M, Hokland P, Juhl C O, Madsen G, Mortensen J, Moller-Nielsen C, Hanberg-Sorenesn F, Hokland M. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surgery 1992; 79: 513–516
   PubMed Web of Science ®Google Scholar
• Vamvakas E C. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36: 175–186
   PubMed Web of Science ®Google Scholar
• Blajchman M A. Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: Do we have the answers yet. Transfusion 1997; 37: 121–125
   PubMed Web of Science ®Google Scholar
• Busch M P. Will human immunodeficiency virus p24 antigen screening increase the safety of the blood supply and, if so, at what cost. Transfusion 1995; 35: 536–539
   PubMed Web of Science ®Google Scholar
• Wylie B R. Transfusion transmitted infection: viral and exotic diseases. Anaesth Intens Care 1993; 21: 24–30
   PubMed Web of Science ®Google Scholar
• Anderson K C, Lew M A, Gorgone B C, Martel J, Bean Leamy C, Sullivan B. Transfusion-related sepsis after prolonged platelet storage. Am J Med 1986; 81: 405–111
   PubMed Web of Science ®Google Scholar
• Morrow J F, Braine H G, Kickler T S, Ness P M, Dick J D, Fuller A K. Septic reactions to platelet transfusions. J Am Med Assoc 1991; 266: 555–558
   PubMed Web of Science ®Google Scholar
• Heal J M, Jones M E, Forey J, Chaudhry A, Stricof R L. Fatal Salmonella septicemia after platelet transfusion. Transfusion 1987; 27: 2–5
   PubMed Web of Science ®Google Scholar
• Chiu E KW, Yuen K Y, Lie A KW, Liang R, Lau Y L, Lee A CW, Kwong Y L, Wong S, Ng M H, Chan T K. A prospective study of symptomatic bacteremia following platelet transfusion and its management. Transfusion 1994; 34: 950–954
   PubMed Web of Science ®Google Scholar
• Barrett B B, Andersen J W, Anderson K C. Strategies for the avoidance of bacterial contamination of blood components. Transfusion 1993; 33: 228–233
   PubMed Web of Science ®Google Scholar
• Klein H G, Dodd R Y, Ness P M, Fratantoni J A, Nemo G J. Current status of microbial contamination of blood components: summary of a conference. Transfusion 1997; 37: 95–101
   PubMed Web of Science ®Google Scholar
• Leiby D A, Kerr K L, Campos J M, Dodd R Y. A retrospective analysis of microbial contaminants in outdated random-donor platelets from multiple sites. Transfusion 1997; 37: 18–24
   PubMed Web of Science ®Google Scholar
• Goldman M, Roy G, Frechette N, Decary F, Massicotte L, Delage G. Evaluation of donor skin disinfection methods. Tranfusion 1997; 37: 309–312
   PubMed Web of Science ®Google Scholar
• Yomtovian R, Lazarus H M, Goodnough L T, Hirschler N V, Morrissey A M, Jacobs M R. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993; 33: 902–909
   PubMed Web of Science ®Google Scholar
• Brecher M E, Hogan J J, Boothe G, Kerr A, McClannan L, Yomtovian R, Chongokolwatana V, Tegtmeir G, Henderson S, Pineda A, Hailing V, Kemper M, Kuramato K, Holland P V, Longiaru M. Platelet bacterial contamination and the use of a chemiluminescence-linked universal bacterial ribosomal RNA gene probe. Transfusion 1994; 34: 70–755
   Google Scholar
• Burstain J M, Brecher M E, Workman K, Foster M, Faber G H, Mair D. Rapid identification of bacterially contaminated platelets using reagent strips: glucose and pH analysis as markers of bacterial metabolism. Transfusion 1997; 37: 255–258
   PubMed Web of Science ®Google Scholar
• Bowden R A, Slichter S J, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3599–3603
   Google Scholar
• Hillyer C D, Emmens R K, Zago-Novaretti M, Berkman E M. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion 1994; 34: 929–934
   PubMed Web of Science ®Google Scholar
• Gilbert L G, Hayes K, Hudson I L, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Lancet 1989; 1: 1228–1231
   PubMed Web of Science ®Google Scholar
• De Graan-Hentzen Y CE, Gratama J W, Mudde G C, Verdonck L F, Houbiers J GA, Brand A, Sebens F W, Van Loon A M, The T H, Willemze R, De Gast G C. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989; 29: 757–760
   PubMed Web of Science ®Google Scholar
• Bowden R A, Slichter S J, Sayers M H, Mori M, Cays M J, Meyers J D. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246–250
   PubMed Web of Science ®Google Scholar
• Beutler E. Platelet transfusions: the 20,000/ul trigger. Blood 1993; 81: 1411–1413
   PubMed Web of Science ®Google Scholar
• Malone D C, Sullivan S D, Black D, Stergachi A. The cost of treating chemotherapy-induced thrombocytopenia. J Clin Oncol, Abstr. 1995
   Google Scholar
• Balducci L, Benson K, Lyman G H, Sanderson R, Fields K, Ballester O F, Elfenbein G J. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion 1993; 33: 665–670
   PubMed Web of Science ®Google Scholar
• Savarese D MF, Hsieh C-C, Stewart F M. Clinical impact of chemotherapy dose escatation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997; 15: 2981–2995
   PubMed Web of Science ®Google Scholar
• Smith J W, Longo D L, Alvord W G, Janik J E, Sharfman W H, Gause B L, Curti B D, Creekmore S P, Holmlund J T, Fenton R G, Sznol M, Miller L L, Shimizu M, Oppenheim J J, Fiem S J, Hursey J C, Powers G C, Urba W J. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756–761
   PubMed Web of Science ®Google Scholar
• Ganser A, Lindemann A, Seipelt G, Ottmann O G, Herrmann F, Eder M, Frisch J, Schulz G, Mertelsmann R, Hoelzer D. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666–676
   PubMed Web of Science ®Google Scholar
• Dale D C, Rodger E, Cebon J, Ramesh N, Hammond W P, Zsebo K M. Long-term treatment of canine cyclic hematopoiesis with recombinant canine stem cell factor. Blood 1995; 85: 74–79
   PubMed Web of Science ®Google Scholar
• Van Gameren M M, Willemse P HB, Mulder N H, Limburg P C, Groen H JM, Vellenga E, De Vries E GE. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994; 84: 1434–1441
   PubMed Web of Science ®Google Scholar
• De Sauvage F J, Hass P E, Spencer S D, Malloy B E, Gurney A L, Spencer S A, Darbonne W C, Henzel W J, Wong S C, Kuang W J, Oles K J, Hultgren B, Solberg L A, Goeddel D V, Eaton D L. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533–538
   PubMed Web of Science ®Google Scholar
• Lok S, Kaushansky K, Holly R D, Kuijper J L, Lofton-Day C E, Oort P J, Grant F J, Heipel M D, Burkhead S K, Kramer J M, Bell L A, Sprecher C A, Blumberg H, Johnson R, Prunkard D, Ching A FT, Mathews S L, Bailey M C, Forstrom J W, Buddie M M, Osborn S G, Evans S J, Sheppard P O, Presnell S R, O'Hara P J, Hagen F S, Roth G J, Foster D C. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565–568
   PubMed Web of Science ®Google Scholar
• Leonard J P, Quinto C M, Kozitza M K, Neben T Y, Goldman S J. Recombinant human interleukin-1 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 1994; 83: 1499–1506
   PubMed Web of Science ®Google Scholar
• Aster R H. What makes platelets go? The cloning of thrombopoietin. Transfusion 1995; 35: 1–3
   PubMed Web of Science ®Google Scholar
• Broudy V C, Lin N L, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine magakaryocyte ploidy in vitro. Blood 1995; 85: 1719–1726
   PubMed Web of Science ®Google Scholar
• Basser R L, Rasko J EJ, Clarke K, Cebon J, Green M D, Grigg A P, Zalcberg J, Cohen B, Obryne J, Menchaca D M, Fox R M, Begley C G. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118–3128
   PubMed Web of Science ®Google Scholar
• Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheriden W, Menchaca D, Tomita D, Ozer H, Harker L. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404–409
   PubMed Web of Science ®Google Scholar
• Du X X, Williams D A. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 1994; 83: 2023–2030
   PubMed Web of Science ®Google Scholar
• Gordon M S, McCaskill-Stevens W J, Battiato L A, Loewy J, Loesch D, Breeden E, Hoffman R, Beach K J, Kuca B, Kaye J, Sledge G W, Jr. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615–3624
   PubMed Web of Science ®Google Scholar
• Isaacs C, Robert N J, Bailey F A, Schuster M W, Overmoyer B, Graham M, Cai B, Beach K J, Loewy J W, Kaye J A. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15: 3368–3377
   PubMed Web of Science ®Google Scholar
• Tepler I, Elias L, Smith JW, II, Hussein M, Rosen G, Chang A Y, Moore J O, Gordon M S, Kuca B, Beach K J, Loewy J W, Garnick M B, Kaye J A. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607–3614
   PubMed Web of Science ®Google Scholar